DRI Healthcare Exercises Put Option on Ekterly for $178M Gain
Event summary
- DRI Healthcare reported record Q2 2026 results with $50.1M in total income and a 92% Adjusted EBITDA margin.
- The company exercised its put option on Ekterly for a net repurchase price of ~$178M, representing a 1.5x return on purchase price.
- FDA approved Viridian's Lumvoa (veligrotug) for thyroid eye disease treatment, triggering a $75M milestone payment to DRI Healthcare.
- DRI Healthcare appointed Dr. Sheila Singh and Dr. Yasir Al-Wakeel to its board of trustees.
The big picture
DRI Healthcare's strong Q2 performance underscores its expertise in pharmaceutical royalty monetization, particularly in navigating regulatory approvals and optimizing asset exits. The $178M gain from Ekterly highlights the firm's ability to capitalize on strategic opportunities within its portfolio, while the board appointments suggest a focus on leveraging biopharmaceutical and financial expertise for future growth.
What we're watching
- Portfolio Optimization
- How DRI Healthcare will deploy the $178M proceeds from Ekterly's sale to enhance its royalty portfolio.
- Regulatory Milestones
- Whether Lumvoa's FDA approval will drive significant revenue growth and additional milestone payments.
- Governance Dynamics
- The impact of Dr. Singh and Dr. Al-Wakeel's appointments on strategic decision-making and long-term growth.